SPY299.08+3.64 1.23%
DIA250.25+5.37 2.19%
IXIC9,340.22+15.63 0.17%

Nomura Instinet Downgrades Deciphera Pharmaceuticals to Neutral, Lowers Price Target of $60

Nomura Instinet analyst Christopher Marai downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Buy to Neutral and lowers the price target from $84 to $60.

Benzinga · 05/07/2020 12:43

Nomura Instinet analyst Christopher Marai downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Buy to Neutral and lowers the price target from $84 to $60.